Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2008 December;50(4) > Panminerva Medica 2008 December;50(4):295-304

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6


eTOC

 

REVIEWS  


Panminerva Medica 2008 December;50(4):295-304

language: English

Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance

Bethea S. W. 1, Nestler J. E. 1,2

1 Division of Endocrinology and Metabolism Department of Internal Medicine Medical College of Virginia Campus Virginia Commonwealth University, Richmond, VA, USA
2 Department of Obstetrics and Gynecology Medical College of Virginia Campus Virginia Commonwealth University, Richmond, VA, USA


FULL TEXT  


The polycystic ovary syndrome (PCOS) affects 5-10% of women of child-bearing age, and the diagnosis carries with it associated metabolic and cardiovascular risk factors that are likely linked to insulin resistance. Consequently, women affected by PCOS are at significant risk for developing type 2 diabetes mellitus, cardiovascular disease, and obstructive sleep apnea. Aggressive screening for glucose intolerance and cardiovascular risk factors should be performed in all PCOS patients, and, when indicated by symptomatology, affected women should be screened for sleep apnea. Long-term goals of therapy should focus on prevention of these comorbidities.

top of page

Publication History

Cite this article as

Corresponding author e-mail